---
title: "Viking Therapeutics' VK2735 improves BMI category in 74% of patients in 13-week Phase 2 trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305578038.md"
description: "Viking Therapeutics reported that its injectable obesity drug VK2735 improved BMI categories in 74% of patients during a 13-week Phase 2 VENTURE trial, outperforming placebo. Participants with improved classifications showed greater reductions in cardiovascular and metabolic risk markers. The company is currently conducting the Phase 3 VANQUISH program for weekly VK2735 injections, with completion expected in 2027."
datetime: "2026-11-15T17:05:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305578038.md)
  - [en](https://longbridge.com/en/news/305578038.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305578038.md)
generator: "portal-rs"
---

# Viking Therapeutics' VK2735 improves BMI category in 74% of patients in 13-week Phase 2 trial

-   Viking Therapeutics presented new results from its Phase 2 VENTURE obesity trial of injectable VK2735 at ObesityWeek 2026. \* Most treated participants improved their obesity classification over 13 weeks, outperforming placebo; none shifted to a higher BMI category. \* Participants whose obesity classification improved showed greater reductions in cardiovascular and metabolic risk markers than those whose classification remained unchanged. \* The ongoing Phase 3 VANQUISH program evaluates weekly injectable VK2735, with trial completion expected in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611151205PR\_NEWS\_USPR\_\_\_\_\_LA98030) on November 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)

## Related News & Research

- [Viking Therapeutics (VKTX) Could Be 77% Undervalued As VK2735 Obesity Data Draws Focus](https://longbridge.com/en/news/305696719.md)
- [Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026 | VKTX Stock News](https://longbridge.com/en/news/305578185.md)
- [Viking Therapeutics (VKTX) Stock Trades At A Premium To Book Value](https://longbridge.com/en/news/306273528.md)
- [Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028](https://longbridge.com/en/news/305443895.md)
- [VKTX: VK2735 showed durable weight loss on less-frequent dosing; Phase 3 readouts lie ahead](https://longbridge.com/en/news/305922449.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**